Novo Holdings Venture Investments is an evergreen venture fund investing >$500M annually in both private and public life sciences companies, making it one of the most active life sciences venture capital investors globally.

Advance commercial planning efforts by providing in-depth, objective insights into Genentech's current and future markets, product performance, customers and competitors.- HER2 Franchise- Ophthalmology Franchise

Examples of prior projects include:- Sum-of-the-parts valuation and opportunity assessment for a mid-sized biotech company in the respiratory disease space- Investment opportunity evaluation in the next-gen sequencing space for an Asian sovereign wealth fund- Strategic plan development and growth opportunity assessment in the single cell analysis market for a business unit of a leading med tech company- Acquisition target sourcing in the digital health space for the clinical diagnostics division of a large US-based pharmaceutical company - Business development screen for assets targeting GI diseases- Due diligence of an acquisition target in the wound care market

Helped launch life sciences companies and supported the growth of the biotech industry in San Francisco with the team at QB3 and Mission Bay Capital.

Mission Bay Capital is a seed stage venture fund designed to support early stage spinouts from the University of California system.

Awarded an A.P. Giannini Foundation Fellowship to study the mechanisms controlling cellular lipid synthesis and storage.Organized a new series of research-in-progress seminars focused on cellular energy metabolism at the UCSF Mission Bay campus, fostering collaboration between researchers at the Gladstone Institutes and UCSF.

Performed prior art searches and evaluated marketing opportunities for new technologies developed at Yale. Established contact with corporate partners regarding licensing agreements.